Home Newsfeeds MKM Partners Assumes Matador Resources at Buy

MKM Partners Assumes Matador Resources at Buy

MKM Partners analyst Leo Mariani assumes Matador Resources (NYSE:MTDR) with a Buy rating.

byBenzinga Newsdesk

September 21, 2022

1 minute read

MKM Partners analyst Leo Mariani assumes Matador Resources (NYSE:MTDR) with a Buy rating.

Analyst Ratings

Expert Ratings For Colgate-Palmolive

By Benzinga Insights

April 30, 12:00 PM

In the latest quarter, 10 analysts provided ratings for Colgate-Palmolive (NYSE:CL), showcasing a mix of bullish and bearish…

Art’s Way Manufacturing Announces 10-Year High Agricultural Product Sales And $1.2M Of Operating Income In Agricultural Products Segment

By Happy Mohamed

February 15, 10:06 AM

Art's Way Manufacturing Co., Inc. (NASDAQ:ARTW), a diversified, international manufacturer and distributor of equipment serving agricultural, research and steel cutting needs, announces its financial results for

ARTW

Maravai LifeSciences Sees FY23 EPS $(0.01)-$0.01 Vs $0.06 Est.; Revenue $275M-$285M Vs $308.73M Est.

By Benzinga Newsdesk

November 7, 8:40 PM

Updated Financial Guidance for 2023Maravai's financial guidance for the full year 2023 is based on expectations for its existing business and does not include the financial impact of potential new acquisitions, if any,

MRVI

European Commission Requests Reevaluation Of Opinion On PTC Therapeutics’ Duchenne Dystrophy Drug; Pauses Annual Guidance

By Vandana Singh

May 20, 12:03 PM

PTC Therapeutics announced that the European Commission has asked the CHMP to re-evaluate its negative opinion on the renewal of Translarna's conditional marketing authorization, keeping it available in Europe.

PTCT

MKM Partners Assumes Matador Resources at Buy

Related Posts

Expert Ratings For Colgate-Palmolive

Art’s Way Manufacturing Announces 10-Year High Agricultural Product Sales And $1.2M Of Operating Income In Agricultural Products Segment

Maravai LifeSciences Sees FY23 EPS $(0.01)-$0.01 Vs $0.06 Est.; Revenue $275M-$285M Vs $308.73M Est.

European Commission Requests Reevaluation Of Opinion On PTC Therapeutics’ Duchenne Dystrophy Drug; Pauses Annual Guidance